Search results

288 results

Sorted by Relevance . Sort by Date

  1. NICE approves ground-breaking cholesterol-lowering drug inclisiran

    NICE has today (1 September 2021) issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by Novartis) for people with primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke.

  2. NICE recommends treatment for people with juvenile idiopathic arthritis

    NICE has today (9 September 2021) published final draft guidance which recommends tofacitinib (also known as Xeljanz and made by Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.

  3. NICE announces next steps for ME/CFS guideline

    NICE recognises the importance to patients of the updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) and is keen to move forwards as quickly as possible.

  4. NICE draft guidance recommends abemaciclib for advanced breast cancer

    NICE has today published draft guidance which recommends twice-daily pill abemaciclib (also called Verzenios and made by Eli Lilly) as an option for adults with a type of breast cancer called hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.

  5. Shared decision making underpins good healthcare

    Shared decision making between service users and healthcare professionals is an integral part of healthcare, says NICE, in new guideline recommendations published today.

  6. NICE recommends offering women induced labour earlier in new draft guidance

    Women should be offered induced labour earlier than previously advised to make birth safer for them and their babies, according to draft guidelines published by NICE today (25 May 2021). The updated recommendations strengthen previous advice in the light of new evidence on induction timings.

  7. NICE signs up to join the GetReal Institute

    NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence in health care decision-making.